Non-functioning pituitary adenomas (NFPA) usually present with symptoms of mass effect. Thus, the first-line treatment generally consists of transsphenoidal surgery. Since these tumors are usually large and invasive, post-surgical tumor remnants are common. Active surveillance is the follow-up strategy adopted by most pituitary centers, although the prevalence of residual tumor growth may reach 50% in 5-10 years, often leading to repeat surgery, radiation therapy, or both. NFPA remain the only pituitary tumor type for which no medical therapy has been approved. In this debate, we consider the evidence in favor and against using cabergoline to treat progressing NFPA.

中文翻译：

---

卡麦角林应尝试用于进展中的无功能垂体大腺瘤。

无功能垂体腺瘤 (NFPA) 通常表现为占位效应的症状。因此，一线治疗通常包括经蝶窦手术。由于这些肿瘤通常较大且具有侵袭性，因此术后肿瘤残留很常见。主动监测是大多数垂体中心采用的随访策略，尽管残留肿瘤生长的患病率可能在 5-10 年内达到 50%，通常会导致重复手术、放疗或两者兼而有之。NFPA 仍然是唯一一种尚未批准药物治疗的垂体肿瘤类型。在这场辩论中，我们考虑了支持和反对使用卡麦角林治疗进展性 NFPA 的证据。